Simbarashe Takuva

8PUBLICATIONS
75CO-AUTHORS
Innate immunityDisease surveillanceMajor global burdens of diseaseRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 04, 2026
Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.

|Mar 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg

|Jun 21, 2022
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.

Simbarashe Takuva, Azwidhwi Takalani, Ishen Seocharan

|Jul 07, 2021
Incidence of cardiometabolic diseases in a Lesotho HIV cohort: Evidence for policy decision-making.

Motlalepula Sebilo, Neo R T Ledibane, Simbarashe Takuva

|Mar 24, 2021
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.

Glenda E Gray, Linda-Gail Bekker, Fatima Laher

|Mar 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Lawrence Corey, Peter B Gilbert, Michal Juraska

Pageof 2

Frequent Collaborators

4 joint publications

Lawrence Corey

4 joint publications

Glenda Gray

2 joint publications

Olivier Van Der Meeren

2 joint publications

Vernon Louw